Premium
Resveratrol feeding may be therapeutic for dystrophic skeletal muscle
Author(s) -
Selsby Joshua T.,
Morine Kevin,
Pendrak Klara,
Tian Z.,
Blanco Erica,
Barton Elisabeth R,
Sweeney H Lee
Publication year - 2009
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.23.1_supplement.600.2
Subject(s) - resveratrol , skeletal muscle , endocrinology , medicine , chemistry , transgene , biology , pharmacology , biochemistry , gene
Increased PGC‐1α, either through a transgenic animal or gene transfer, provides therapeutic benefit to dystrophic skeletal muscle likely by increasing slow and oxidative protein expression. Resveratrol has been shown to activate SIRT‐1, a known deacetylase capable of acting on and increasing the activity of PGC‐1α. The purpose of this investigation was to determine if resveratrol supplementation could rescue dystrophic skeletal muscle. We hypothesized that daily feeding of resveratrol would improve muscle function in a similar fashion as PGC‐1α over‐expression. To test this hypothesis, 1‐mo old mdx mice were either fed a control diet (Con) or a diet containing resveratrol at 100 mg/kg/day (Res) for 8 wks. Following intervention, absolute muscle mass was reduced 18‐30% in the Res group compared to Con, however, body mass was also reduced in the Res group by 20% compared to Con. Relative muscle mass was similar between groups, except for the EDL, which was significantly smaller in the Res group. Solei in the Res group were more fatigue resistant than in the Con group, however, resistance to contraction induced injury was similar between groups. These data indicate that partial rescue of dystrophic pathology is possible through resveratrol. Perhaps, alternative sources or doses of resveratrol will provide a greater response. U54‐ AR052646 , F32AR055005‐01, AR053461 , and PPMD.